FDA delays decision on first drug to prevent HIV

By Qineqt:Last Friday, the Food and Drug Administration (FDA) delayed the approval of two HIV-drugs, Truvada and Quad, until September. However, Truvada has already been a treatment drug and is prescribed by some doctors as a preventive measure as well.

The Burrill Report submits: by Marie Daghlian

After a decade-long battle over access to emergency contraception, a federal judge on Friday ordered US regulators to make the morning-after pill available over the counter without limits on age.

Bret Jensen submits:Company Overview: Gilead Sciences, Inc. (GILD), a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide.

ByStock Whisper:Gilead Sciences' (GILD) stock price has almost doubled in the last 52 weeks. The company is successfully rolling one after another drug into the market. It has been successful in receiving FDA approval for Quad and Truvada (for HIV prevention), and is now focusing on the Sofobuvir cocktail for Hepatitis C treatment. I believe at a P/E of 17x, GILD is a bargain for any portfolio.

By Zacks.com: One of the world's largest drug makers, Gilead Sciences, Inc. (GILD) is riding on the crest of a series of successes.

FDA regulators approved Truvada, a Gilead Sciences HIV drug, for use in certain healthy people to help prevent them from contracting the virus that causes AIDS.

A panel of federal health advisers has endorsed the first drug shown to prevent HIV infection in healthy people, clearing the way for a potentially landmark approval in the 30-year-old effort against the virus that causes AIDS.